Humoral response in cancer patients appears early in cancer progression and can be used for 33 diagnosis, including early detection. By using human recombinant protein and T7 phages 34 microarrays displaying colorectal cancer (CRC)-specific peptides, we previously selected 6 35 phages and 6 human recombinant proteins as tumor-associated antigens (TAAs) with high 36 diagnostic value. After completing validation in biological samples, TAAs were classified 37 according to their correlation, redundancy in reactivity patterns and multiplex diagnostic 38
Colorectal cancer (CRC) is the major cause of cancer-associated mortality in developed 48 countries [1] . An early detection of the disease is critical for higher patient survival rates. The 49 most common CRC protein biomarker, CEA, is mostly adequate for advanced stages and for 50 monitoring recurrence of the disease [2, 3] . Final outcome of patients improves substantially 51 with early detection of CRC, with 5-year survival rates of 91.1%, %, 69.8% and 11.4% for 52 localized, regional and distant stages, respectively (Surveillance Epidemiology and End Results 53 (2011). National Cancer Institute. USA). 54
In cancer, self-proteins altered before or during tumor formation and progression, can 55 elicit an immune response when they are released from the tumoral cells to the blood of the 56 patients [4] [5] [6] [7] . These proteins can suffer point mutations, misfolding, truncation, over-57 expression, aberrant splicing or degradation as a consequence of mutations in the DNA of 58 tumoral cells [8] [9] [10] [11] [12] [13] [14] . Patients with cancer spontaneously develop a humoral response against 59 these altered tumor-associated autoantigens (TAAs), producing autoantibodies [15] [16] [17] . The 60 immune response occurs early during tumor development. Measuring levels of autoantibodies 61 in blood would allow for a non-invasive cancer diagnosis at earlier stages, providing an 62 effective method for cancer screening and preclinical diagnosis. This approach has already 63 been successfully used in other cancers [4, 15, [18] [19] [20] [21] [22] [23] [24] . 64
The development of noninvasive screening tests would represent a major advance in 65 the fight against cancer, as pre-clinical or early diagnosis are considered the best prevention to 66 reduce cancer mortality. Screening tests based on autoantibodies present in serum or plasma 67 of cancer patients are a promising alternative to fulfill this goal. Because antibodies are very 68 stable molecules and their differences between control and case samples are easier to detect, 69
we have used thehumoralresponseincancerpatients'toidentify autoantibodies and their 70 respective TAAs as biomarkers of CRC. 71 117
Dot blot and western blot analysis. 118
Dot blot analysis to determine the expression of FGFR4, SRC and MST1/STK4 in different 119 healthy and cancer tissues was performed using DiscoverLight Human Tissue Arrays (Pierce). 120
For western blot analysis, protein extracts from CRC paired tissues were prepared as described 121 [28, 29] . Briefly, 50 g of protein extracts were run in 10% SDS-PAGE and transferred to 122 nitrocellulose membranes (Hybond-C extra). After blocking, membranes were incubated 123 overnight at 4ºC with optimized dilutions of specific mono-or polyclonal antibodies (FGFR4, 124 Santa Cruz Biotechnology; SRC, R&D Systems; MST1, Cell Signaling). Immunodetection on the 125 membranes was achieved by using peroxidase-conjugated secondary antibodies (Sigma). The 126 ECL signal was developed with SuperSignal West Femto substrate (Thermo). The abundance of 127 the proteins in dot blot and western blot assays was determined by densitometry using 128 Quantity One 1D Analysis Software v4.6 (Bio-Rad Laboratories). 129 130
ELISA tests 131
ELISA experiments with full-length recombinant proteins were performed as described before 132
[18]. Briefly, microtiter plates (Maxisorp, Nunc) were coated overnight with 0.3 g of the 133 purified proteins in 50 l of PBS. For multiplex analysis, we coated the same well with 0.3 g of 134 each protein, PIM1, MAPKAPK3 and FGFR4, in 50 l of PBS. After washing three times with 135 PBS, plates were blocked with 3% skimmed milk in PBS (MPBS) for 2 h at room temperature. 136
Following additional washing, serum samples (dilution 1:50 in 3% MPBS) were incubated for 2 137 h at room temperature. After washing, anti-human IgG peroxidase-labelled (DAKO) at a 1:3000 138 dilution in 3% MPBS was added for 2 h at room temperature. Then, the signal was developed 139 with 3,3′,5,5′-tetramethylbenzidine (TMB) substrate (Sigma likely that we find a better combined classifier if the correlation is small between two markers 159 than if the two markers are highly correlated. Note, however, that in some cases (see below 160 the example of GTF2i and SREBF2 phages), markers with high correlation can, however, do a 161 good patient discrimination when used together if, for instance, the ratio between the two 162 markers differs between types of patients. 163
Logistic regression with variable selection using Akaike Information Criterion (AIC) was 164 bootstrapped as previously described with minor modifications [18, 27] . Bootstrapping was 165 applied to the complete procedure (i.e. including the variable selection step) to determine the 166 effect of the combination of the biomarkers together with the structural variables sex and age 167 of the patients in order to determine their importance in the model since these variables 168 usually affect most of the biological process. Within each bootstrap replication (and with the 169 complete data set) variable selection was carried out using AIC. Logistic regression was fitted in 170 R [30] using the function "glm" (from R) andthefunction"lrm"fromthe"rms"packagefor R 171 by F. Harrell significantly different autoantibody levels in CRC sera (p ≤ 0.04) and 43 phages differentially 179 recognized by CRC patients. A total of 11 TAAs were selected based on the statistical 180 significance and diagnostic prevalence. From this set, seven full length recombinant proteins 181 were expressed in E. coli and purified to homogeneity ( Fig. 1 ) and four phages displaying CRC-182 specific peptides were amplified and purified. MST1/STK4, SULF1, ACVR2B, SRC, MAPKAPK3, 183 FGFR4 and PIM1 recombinant proteins and NHSL1, SREBF2, GRN and GTF2i-like phage lysates 184
were tested by ELISA to assess their ability to discriminate between CRC sera and healthy 185 control sera. We used an independent cohort of 96 samples (50 colorectal cancer, including 17 186 samples from early colorectal cancer stages (A-B), and 46 control samples (Fig. 2) . 187
For individual TAAs, autoantibody titers in CRC group were significantly higher than in 188 control group by ELISA, except for ACVR2B, as expected [18] (Supplementary Table 1) , p values 189 were statistically significant, except for GRN phage. Using ROC curves analysis, we observed 190 that all purified proteins and phages showed individual diagnostic potential for discriminating 191 between CRC and reference control samples, with AUCs ≥52% (Table 2) (Fig. 3A) . 209
For further confirmation, FGFR4 and SRC were analyzed by immunoblotting with 210 protein samples from colorectal cancer and reference cells ( Then, we studied the correlation between the identified TAAs for redundancy and 226 discrimination ability for CRC diagnosis. This information can be used to develop a multiplex 227 test, since those with high correlation values can be used together. We plotted the ELISA 228 results for all pairs of TAAs. Many TAAs showed low correlation between them (≤0.34), 229 indicating that their reactivity was not redundant and they discriminated better CRC from 230 controls if tested separately (Supplementary Table 3 ). However, we found different scenarios 231 for several pairs of TAAs. MAPKAPK3 and ACVR2B showed a small linear correlation (0.34) and, 232 thus, gave together a good discriminatory ability (Fig. 4A) , since the amount of redundant 233 information each one of the markers provides about the other marker is small. In contrast, 234 PIM1 and MAPKAPK3, with a correlation of 0.709, FGFR4 and PIM1 with 0.592 and FGFR4 and 235 MAPKAPK3 with 0.635, showed a very similar predictive ability in recognizing the same 236 patient'spopulation, suggesting the using each of these three markers individually and 237 separately, in the same model, would not improve the discrimination ability of a panel 238 predictor for CRC diagnosis. Therefore, PIM1, MAPKAPK3 and FGFR4 can be tested together to 239 enhance the diagnostic ability of the panel. Multiplexing the assay reduces the amount of sera 240 needed and simplifies the test. Indeed, when multiplexing FGFR4, PIM1 and MAPKAPK3, the 241 AUC, sensitivity and specificity increased to 79.7%, 84.8% and 79.6%, respectively (Table 2) . For 242 early diagnosis purposes, we observed again that multiplexing these antigens produced an 243 increase in the AUC, sensitivity and specificity in comparison to the proteins separately 244 (Supplementary Table 2) . 245
Regarding the correlation between the other markers, we noticed a high correlation 246 (0.82) for two phages: GTF2i and SREBF2. Phages GTF2i and SREBF2 appeared in most of the 247 multivariate models fitted (see section 3.5, for description of bootstrapping). The AUC of each 248 of these phages on their own is small, but GTF2i and SREBF2 together can do a good 249 discrimination (Fig. 4B ). For a fixed absorbance level for SREBF2 (e.g., orange dot-slash 250 rectangle), the probability that a patient be considered disease-free increased with the levels 251 of GTF2i. In contrast, if we fix the level of GTF2i (e.g., green slash rectangle) the probability 252 that a patient is considered diseased increases as we increase the value of SREBF2. By using 253 those two variables (SREBF2 and GTF2i) the two classes can be separated, as the "normals" 254 tend to be those that have a high GTF2i value relative to the amount of SREBF2. Although the 255 two markers showed a high correlation (0.82), they can discriminate between tumor and 256 normal patients because the ratio GTF2i/SREBF2 was different between tumors and controls 257 (that ratio is higher for controls than tumors). Interestingly, although the ratio GTF2i/SREBF2 258 was highly discriminatory, there was not enough evidence of significant interaction (p value: 259 0.1448) to specify an interaction between them in the logistic regressions. In summary, 260 correlation between independent variables is a property of the relationship of these 261 independent variables, but is not inherently related to the joint relationship of the 262 independent and the dependent variables (the disease status in this case) and their 263 discriminatory capability. It should be analyzed case by case. 264 265
3.4
Building an optimized predictor panel for colorectal cancer 266
Next, we investigated which combination of proteins and phages shows the best diagnostic 267 ability for CRC. ELISA data for each TAA and the combination of FGFR4, PIM1 and MAPKAPK3, 268 which were used together, were fitted to a logistic curve and performed logistic regressions. 269 Different models were produced using different combinations of phages and proteins. 270
The combination of three phages displaying peptides homologues to GTF2i, NHSL1 and 271 SREBF2 and four proteins PIM1, ACVR2B, MAPKAPK3 and FGFR4, with the data of the last 272 three proteins altogether, showed the best ability to discriminate among CRC serum samples 273 and reference sera (Fig. 5A) . ROC curves obtained after combining the results for the seven 274
TAAs showed an AUC of 94%, with a sensitivity and specificity of 89.1% and 90%, respectively. 275
Interestingly, using the 7 TAAs optimized predictor with CRC serum samples 276 corresponding to early A-B stages, we found an AUC of 90%, with a sensitivity and specificity of 277 88.2% and 82.6%, respectively (Fig. 5B ). With these same samples, CEA gave an AUC of 74%, 278 with a sensitivity and specificity of 82.4% and 63.0%, respectively (Fig. 5C) . 279
Bootstrapping analysis confirmed the predictor panel 281
We performed bootstrapping (using 1000 bootstrap samples) to obtain a bias-corrected AUC 282 and to validate this TAA combination for CRC screening. The initial model included linear terms 283 for all phages and proteins, together with the gender and age of the patients. Since the gender 284 and age of the patients usually affect multiple biological processes, they were included in the 285 analysis to know if they affect the panel of biomarkers. In addition, we also combined the 286 model with and without CEA quantification in all samples to determine if CEA levels in serum 287 could improve the model. With CEA in this model, the value of the bias-corrected AUC was 288 92.5%. The model without CEA, gave a bias-corrected AUC of 90.5%. Both models got better 289 AUC than CEA alone, which gave a bias-corrected AUC of 82.4%. 290
After variable selection, using Akaike Information Criterion, the final model with CEA 291 retained the same three phages displaying homologue peptides to GTF2i, NHSL1 and SREBF2 292 and four full-length recombinant proteins PIM1, ACVR2B, MAPKAPK3 and FGFR4 (Table 3) . To 293 avoid an overestimation of the predictive capacity of the model, we obtained bias-corrected 294 estimates of the AUC, by bootstrapping the complete process of variable selection. The bias-295 corrected AUC was 91.6%. Bootstrapping also provided information on the stability of the 296 selection procedure: among the bootstrapped models, most contained between 7 and 11 297 variables. Interestingly, two of the variables appeared in all the models: GTF2i and SREBF2 298 phages. ACVR2B appeared in 96% of the models, PIM1, MAPKAPK3 and FGFR4 in 92%, CEA in 299 86% and, finally, NHSL1 phage in 75% of the models. Regarding the final model without CEA 300 after variable selection, we observed that the model contained the same variables, with a bias-301 corrected AUC of 90.5%, slightly lower than the model including CEA (Supplementary Table 4) . 302
Then, we tested the value of the prediction for early diagnosis purposes. We started 303 from the best model composed of three phages and four proteins plus sex and age, as 304 structural variables. The bias-corrected AUC using bootstrapping was 90% for stages A-B. After observing a high correlation between the three markers: PIM1, MAPKAPK3 and 319 FGFR4, they were combined in a multiplex assay, instead of testing one antigen at a time. 320
However, ACVR2B and three phages were tested separately as they react with different 321 patients. Further experiments might increase the specificity and sensitivity of the diagnostic 322 1-p) ), where p is the probability of being CRC patient, when the value of all the other 433 terms in the model is 0. The intercept, therefore, represents the differences in the probability 434 of being CRC or control patient, even if there are no effects of the independent variables. 435
Estimate, estimated coefficient (slope). A negative coefficient would indicate that the 436 probability of being CRC patient decreased when the immune response of the marker 437 increases; Std. Error, the standard error of the specified variable; z value or Wald statistic, 438 which is exactly equal to the estimated coefficient divided by its standard error; Pr(> z ), p-439 value from the Wald test for that specific coefficient comparing the z-value against a standard 440 normal; * to ***, grade of significance. 441 a . GTF2i-phage coefficient is negative although its reactivity is higher in CRC than control due to 442 the high correlation in the immune response between GTF2i-phage and SREBF2-phage (see 443 legend to Fig.4B) . CRC from control samples because of the ratio GTF2i-phage/SREBF2-phage is larger for 482 controls than CRC samples. The dotted black line separates CRC samples from controls with a 483 logistic regression model that included only GTF2i-phage and SREBF2-phage. As an illustration, 484 within the orange dot slash rectangle, the probability that a patient is control increased with 485 the levels of autoantibodies to GTF2i-phage for a fixed absorbance level of SREBF2-phage. 486
Within the green slash rectangle, the probability that a patient is CRC positive increased as the 487 reactivity with SREBF2-phage increased for a fixed absorbance level of GTF2i-phage. 211N  211T  299N  299T  699N  699T  700N  700T  704N  704T  713N  713T  FGFR4 
